EBC-46

EBC-46

Biomarker Endpoints in EBC-46 Clinical Research: What Researchers Are Measuring and Why

The biomarkers chosen for EBC-46 trials are not arbitrary — they reflect the current scientific understanding of how tigilanol tiglate kills tumours. Here's what researchers are measuring and why it matters.

EBC-46

Diacylglycerol Mimicry: Why EBC-46 Binds Protein Kinase C With Unusual Selectivity

EBC-46 doesn't force its way into cells — it speaks their language. By mimicking diacylglycerol, the compound activates PKC with a precision that synthetic drugs rarely achieve. Here's the molecular story.

EBC-46

Compassionate Use and Expanded Access: What They Mean for Tigilanol Tiglate Patients

Before a drug achieves full approval, compassionate use and expanded access programmes can provide a legal pathway for patients who have no other options. Here's how they apply to tigilanol tiglate.

EBC-46

How to Dose Blushwood Berry Extract: A Practical Guide to EBC-46 Supplementation

Supplement manufacturers have developed EBC-46 dosing protocols based on formulation research and real-world feedback. Here's what the data suggests about when and how to take it.

EBC-46

Blood Markers, Doctor Reactions, and the Blushwood Reports That Demand Scientific Attention

When a doctor looks up blushwood extract after seeing unexplained improvements in a patient's blood work, something remarkable is happening — and the scientific community should be paying attention.

EBC-46

The Diterpene Ester Family: Where EBC-46 Fits in Plant-Derived Chemistry

EBC-46 belongs to the diterpene ester class — a family of plant compounds with extraordinary biological potency. Understanding this chemical context reveals why the Blushwood berry has captivated researchers.

EBC-46

Patient Selection in EBC-46 Trials: Who Qualifies and Why Tumour Accessibility Matters

Not every cancer patient qualifies for EBC-46 clinical trials. Tumour accessibility, prior treatment history, and lesion characteristics all determine eligibility — here is what the inclusion criteria reveal.

EBC-46

Vascular Disruption Without Systemic Toxicity: How EBC-46 Starves Tumours From Within

EBC-46 destroys the blood vessels feeding a tumour within hours of injection — cutting off oxygen and nutrients while leaving surrounding healthy vasculature intact. Here is the biology behind this precision.

EBC-46

Compassionate Use Pathways for Tigilanol Tiglate: How Patients Access Unapproved Cancer Drugs

Compassionate use and expanded access programmes could allow cancer patients to receive tigilanol tiglate before formal Phase III approval — here is how the regulatory framework works.

EBC-46

Hylandia dockrillii vs Fontainea picrosperma: The Blushwood Misidentification That Has Misled the Internet for a Decade

Two plants share the name Blushwood, but only one contains EBC-46. A decade of media misidentification has wrongly attributed tigilanol tiglate to Hylandia dockrillii — here is the full story.

EBC-46

Topical Blushwood Berry Extract: What Users Report and What the Science Says

Verified buyers report striking results with blushwood berry extract — from inflammation and energy to skin changes and outcomes that surprised their doctors. Science should be paying attention.

EBC-46

Fontainea picrosperma: The Rainforest Tree That Produces EBC-46

Fontainea picrosperma grows only in north Queensland's Wet Tropics and produces a pharmacologically extraordinary compound. The full extent of what it can do remains one of botany's most compelling open questions.